Hyperion ceases substantial holding in Fisher & Paykel Healthcare

Hyperion Asset Management Limited has ceased to be a substantial product holder in Fisher & Paykel Healthcare Corp. Ltd as of November 10, 2025. The disclosure, made on November 12, 2025, indicates a decrease in their total percentage held in the company from 5.182% to 4.981%. Previously, Hyperion held 30,432,527 ordinary shares, which has now been reduced to 29,251,816 ordinary shares out of a total of 587,262,856 shares in the class.

The change in Hyperion's holding was a result of a series of transactions, primarily sales, that took place between October 21 and November 10, 2025. On November 3, 2025, Hyperion sold 756,206 shares for -NZD 27,591,258.64. Further sales on November 6 and November 10 involved 475,651 shares for -NZD 17,963,079.78 and 120,326 shares for -NZD 4,625,159.89, respectively.

The company's previous last disclosure of substantial holding was on October 20, 2025. Terence Kwong, company secretary, certified the disclosure from their address at Level 19, 307 Queen St, Brisbane QLD 4000, Australia.